CAR T-cells For Ovarian Cancers with Anixa Biosciences' Amit Kumar, Ph.D.
Source: Bioprocess Online
While success has been seen in animal models, solid tumors have proved a vexing challenge for CAR T-cell therapies. On this week's episode of the Business of Biotech, we're joined by Anixa Biosciences Chairman, President, & CEO Amit Kumar, Ph.D. Dr. Kumar shares on the company's progress with a CAR T-cell therapy that aims to attack both tumor cells and the tumor vasculature, in hopes that it might be the first to destroy solid breast and ovarian cancers.
This website uses cookies to ensure you get the best experience on our website. Learn more